PMID- 35366926
OWN - NLM
STAT- MEDLINE
DCOM- 20220405
LR  - 20220408
IS  - 1748-717X (Electronic)
IS  - 1748-717X (Linking)
VI  - 17
IP  - 1
DP  - 2022 Apr 2
TI  - Safety of stereotactic body radiation therapy for localized prostate cancer 
      without treatment planning MRI.
PG  - 66
LID - 10.1186/s13014-022-02026-1 [doi]
LID - 66
AB  - BACKGROUND: The use of treatment planning prostate MRI for Stereotactic Body 
      Radiation Therapy (SBRT) is largely a standard, yet not all patients can receive 
      MRI for a variety of clinical reasons. Thus, we aim to investigate the safety of 
      patients who received CT alone based SBRT planning for the definitive treatment 
      of localized prostate cancer. METHODS: Our study analyzed 3410 patients with 
      localized prostate cancer who were treated with SBRT at a single academic 
      institution between 2006 and 2020. Acute and late toxicity was evaluated using 
      the Common Terminology Criteria for Adverse Events version 5.0. Expanded Prostate 
      Cancer Index Composite (EPIC) questionnaires evaluated QOL and PSA nadir was 
      evaluated to detect biochemical failures. RESULTS: A total of 162 patients 
      (4.75%) received CT alone for treatment planning. The CT alone group was older 
      relative to the MRI group (69.9 vs 67.2, p < 0.001) and had higher risk and grade 
      disease (p < 0.001). Additionally, the CT group exhibited a trend in larger CTVs 
      (82.56 cc vs 76.90 cc; p = 0.055), lower total radiation doses (p = 0.048), and 
      more frequent pelvic nodal radiation versus the MRI group (p < 0.001). There were 
      only two reported cases of Grade 3 + toxicity within the CT alone group. Quality 
      of life data within the CT alone group revealed declines in urinary and bowel 
      scores at one month with return to baseline at subsequent follow up. Early 
      biochemical failure data at median time of 2.3 years revealed five failures by 
      Phoenix definition. CONCLUSIONS: While clinical differences existed between the 
      MRI and CT alone group, we observed tolerable toxicity profiles in the CT alone 
      cohort, which was further supported by EPIC questionnaire data. The overall 
      clinical outcomes appear comparable in patients unable to receive MRI for their 
      SBRT treatment plan with early clinical follow up.
CI  - (c) 2022. The Author(s).
FAU - Amarell, Katherine
AU  - Amarell K
AD  - Department of Radiation Medicine, Georgetown University School of Medicine, 
      Washington D.C., 20007, USA.
FAU - Jaysing, Anna
AU  - Jaysing A
AD  - Department of Radiation Oncology, New York University Long Island School of 
      Medicine, Mineola, MY, 11501, USA.
FAU - Mendez, Christopher
AU  - Mendez C
AD  - Department of Radiation Oncology, Perlmutter Cancer Center at New York University 
      Langone Hospital - Long Island, 150 Amsterdam Ave., New York, NY, 10023, USA.
FAU - Haas, Jonathan A
AU  - Haas JA
AD  - Department of Radiation Oncology, Perlmutter Cancer Center at New York University 
      Langone Hospital - Long Island, 150 Amsterdam Ave., New York, NY, 10023, USA.
FAU - Blacksburg, Seth R
AU  - Blacksburg SR
AD  - Department of Radiation Medicine, Lenox Hill Hospital - Northwell Health, New 
      York, NY, 10075, USA.
FAU - Katz, Aaron E
AU  - Katz AE
AD  - Department of Urology, New York University Long Island School of Medicine, 
      Mineola, NY, 11501, USA.
FAU - Sanchez, Astrid
AU  - Sanchez A
AD  - Department of Radiation Oncology, Perlmutter Cancer Center at New York University 
      Langone Hospital - Long Island, 150 Amsterdam Ave., New York, NY, 10023, USA.
FAU - Tong, Angela
AU  - Tong A
AD  - Department of Radiology, New York University Grossman School of Medicine, New 
      York, NY, 10016, USA.
FAU - Carpenter, Todd
AU  - Carpenter T
AD  - Department of Radiation Oncology, Perlmutter Cancer Center at New York University 
      Langone Hospital - Long Island, 150 Amsterdam Ave., New York, NY, 10023, USA.
FAU - Witten, Matthew
AU  - Witten M
AD  - Department of Radiation Oncology, Perlmutter Cancer Center at New York University 
      Langone Hospital - Long Island, 150 Amsterdam Ave., New York, NY, 10023, USA.
FAU - Collins, Sean P
AU  - Collins SP
AD  - Department of Radiation Medicine, Medstar Georgetown University Hospital, 
      Washington D.C., 20007, USA.
FAU - Lischalk, Jonathan W
AU  - Lischalk JW
AD  - Department of Radiation Oncology, Perlmutter Cancer Center at New York University 
      Langone Hospital - Long Island, 150 Amsterdam Ave., New York, NY, 10023, USA. 
      jonathan.lischalk@nyulangone.org.
LA  - eng
GR  - 20-00-00-1003866/Accuray Research Grant/
PT  - Journal Article
DEP - 20220402
PL  - England
TA  - Radiat Oncol
JT  - Radiation oncology (London, England)
JID - 101265111
SB  - IM
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Prostate
MH  - *Prostatic Neoplasms/diagnostic imaging/radiotherapy
MH  - Quality of Life
MH  - *Radiosurgery/adverse effects
PMC - PMC8977039
OTO - NOTNLM
OT  - Magnetic resonance imaging
OT  - Prostate cancer
OT  - Quality of life
OT  - Stereotactic body radiation therapy
OT  - Toxicity
COIS- Jonathan A. Haas, Seth R. Blacksburg, Sean P. Collins, and Jonathan W. Lischalk 
      are paid speakers for Accuray. The remaining authors have no competing interests.
EDAT- 2022/04/04 06:00
MHDA- 2022/04/06 06:00
PMCR- 2022/04/02
CRDT- 2022/04/03 20:22
PHST- 2021/08/20 00:00 [received]
PHST- 2022/03/09 00:00 [accepted]
PHST- 2022/04/03 20:22 [entrez]
PHST- 2022/04/04 06:00 [pubmed]
PHST- 2022/04/06 06:00 [medline]
PHST- 2022/04/02 00:00 [pmc-release]
AID - 10.1186/s13014-022-02026-1 [pii]
AID - 2026 [pii]
AID - 10.1186/s13014-022-02026-1 [doi]
PST - epublish
SO  - Radiat Oncol. 2022 Apr 2;17(1):66. doi: 10.1186/s13014-022-02026-1.